Ze-gen, Inc.

Ze-gen Names Robertson COO and Prendergast CFO

Ze-gen Names Robertson COO and Prendergast CFO

May 16, 2011

Boston, MA— Ze-gen, Inc., a leading developer and integrator of advanced gasification technology to convert waste streams into synthesis gas (syngas), announced today the promotion of David Robertson to Chief Operating Officer and Mark Prendergast to Chief Financial Officer, replacing Neal Isaacson who has served in this role since August 2009.

Seventh Sense Biosystems, Inc.

Seventh Sense Biosystems Secures $4.5M from $10M Series A Offering

Seventh Sense Biosystems Secures $4.5M from $10M Series A Offering

May 11, 2011

Cambridge, Mass., May 11, 2011 - Seventh Sense Biosystems, Inc., a company redefining blood sampling and health diagnostics with its proprietary Touch Activated Phlebotomy™ (TAP) technology platform, announced today that it has secured $4.5 million of a two-tranche $10 million extension of its Series A financing. The funds raised from existing investors, Flagship Ventures, Polaris Venture Partners and Third Rock Ventures, will be used to advance development of the TAP platform, which enables one-step blood collection in a safe, painless and convenient manner.

Scientific founder of AVEO, Dr. DePinho, named President of the MD Anderson Cancer Center

Scientific founder of AVEO, Dr. DePinho, named President of the MD Anderson Cancer Center

May 16, 2011

Flagship congratulates Ron DePinho, Professor of Medicine (Genetics), Harvard Medical School and Director, Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, on his appointment as President of the MD Anderson Cancer Center at the University of Texas.  Dr. DePinho is world renowned for his research into the molecular and biological mechanisms of cancer, aging, and degenerative diseases.

Black Duck Software, Inc.

Black Duck Software Named Winner of the 2011 New England Innovation Awards Program

Black Duck Software Named Winner of the 2011 New England Innovation Awards Program

May 12, 2011

Waltham, MA -- Nine organizations, including profit and nonprofit entities, were honored at the 25th annual SBANE New England Innovation Award (NEIA) festivities last evening at the Westin Hotel here. As further evidence that innovation can thrive in any field of endeavor, the winners represent firms in such diverse fields as regenerative medicine, software development, organic waste treatment, textiles, dry-erase paint technology, youth services, food packaging, plastics industry and science education.

U.S. Clean Tech Industry At A Crossroads

U.S. Clean Tech Industry At A Crossroads

April 20, 2011

Click on the logo to the right to read a guest blog by Jim Matheson on the New England Clean Energy Council website.

 

Joule Unlimited, Inc.

Joule Secures First of Multiple Sites to Host Solar Fuel Production

Joule Secures First of Multiple Sites to Host Solar Fuel Production

May 5, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Marking another milestone in its advance towards commercialization, Joule Unlimited, Inc. today announced the signing of a lease agreement providing access to 1,200 acres in Lea County, New Mexico, with the potential to scale the project up to 5,000 acres for production of renewable diesel and ethanol directly from sunlight and waste CO2. The agreement with Lea County is the first to be completed as part of Joule’s production facility siting program.

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Presents Preclinical Data on Novel Deuterium-Containing Drug Compound at Antiepileptic Drug Trials XI Conference

Concert Pharmaceuticals Presents Preclinical Data on Novel Deuterium-Containing Drug Compound at Antiepileptic Drug Trials XI Conference

May 2, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that C-10068, a novel deuterium-containing sigma-1 agonist, was found to have activity in preclinical models of epilepsy, neuroprotection and neuropathic pain. C-10068 is based on a molecule that was reported to have preclinical anti-convulsant efficacy, but was limited by poor metabolic stability resulting in low oral bioavailability. Applying its DCE Platform™ (deuterated chemical entity platform), Concert improved the compound’s metabolic stability by selective incorporation of deuterium.

Brain Storm: David Berry Profile in Boston Magazine

Brain Storm: David Berry Profile in Boston Magazine

April 20, 2011

"David Berry is one of the most brilliant thinkers you’ve never heard of. Starting in 2012 he’s going to eliminate our dependence on fossil fuels using little more than algae. (Okay, it’s technically cyanobacteria, but you know what we mean.) He might have done it sooner, but he’s also working on curing cancer and eradicating global hunger."

Excerpts from Boston Magazine story. 

Click Boston Magazine logo to view full story.

Joule Unlimited, Inc.

On the hunt for green-tech game changers

On the hunt for green-tech game changers

April 22, 2011

In a CNET NEWS story, Flagship's Noubar Afeyan was quoted discussing Joule Unlimited and the pace and scale of green technology innovation at the Yale Climate and Energy Institute's annual conference.

Click here to view the full story on cnet.

TARIS Biomedical, Inc.

TARIS CLOSES $18.3 MILLION SERIES B FINANCING

TARIS CLOSES $18.3 MILLION SERIES B FINANCING

April 13, 2011

Lexington, MA – TARIS Biomedical®, a specialty pharmaceutical company pioneering the development of innovative, targeted therapies using drug delivery to treat bladder diseases, announced today that it has raised $18.3 million of new capital in connection with its Series B equity financing. Third Rock Ventures, a new investor, led the round and all existing TARIS investors, Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners, participated. The company’s prior bridge financing was also converted into equity in connection with the round.